Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claims 1-17. (Canceled).

Claim 18. (New) A method for the treatment or inhibition of an infectious disease caused by *Aspergillus fumigatus*, which comprises:

administering an effective amount of a lipopeptide compound [I] of the following formula:



[I]

wherein R^1 is an acyl group, R^2 is hydrogen or hydroxy and R^3 is hydrogen or hydroxy, or a salt thereof, in combination with Amphotericin B, Itraconazole, Nikkomycin X or Flucytosine.

Claim 19. (New) The method of Claim 18, wherein the lipopeptide compound [I] is



or a salt thereof.

Claim 20. (New) A pharmaceutical composition for the prophylactic and/or therapeutic treatment of an infectious disease caused by a fungal pathogen, which comprises:

an effective amount of the lipopeptide compound [I] in Claim 18 in combination with Amphotericin B, Itraconazole, Nikkomycin X or Flucytosine and optionally pharmaceutically acceptable carriers or excipients.

Claim 21. (New) The method of Claim 18, wherein the infectious disease is dermatophytosis, pityriasis versicolor, candidiasis, cryptococcosis, geotrichosis, trichosporosis, aspergillosis, penicilliosis, fusariosis, zygomycosis, sporotrichosis, chromoycosis, coccidiodomycosis, histoplasmosis, blastomycosis, paracoccidioidomycosis, pseudallescheriosis, mycetoma, mycotic keratitis, otomycosis or pneumocystosis.

Claim 22. (New) The method of Claim 18, wherein the pharmaceutically acceptable salt of the lipopeptide compound [I] is formed from an inorganic base.

Claim 23. (New) The method of Claim 18, wherein the pharmaceutically acceptable salt of the lipopeptide compound [I] is formed from an organic base.

Claim 24. (New) The method of Claim 18, wherein said acyl group is aliphatic acyl, aromatic acyl, arylaliphatic acyl or heterocyclicaliphatic acyl.

Claim 25. (New) The method of Claim 24, wherein said aliphatic acyl is alkanoyl selected from the group consisting of formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl and icosanoyl; alkoxycarbonyl selected from the group consisting of methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl and heptyloxycarbonyl; alkylsulfonyl selected from the group consisting of methylsulfonyl and ethylsulfonyl; or alkoxysulfonyl selected from the group consisting of methoxysulfonyl and ethoxysulfonyl.

Claim 26. (New) The method of Claim 24, wherein said aromatic acyl is aroyl selected from the group consisting of benzoyl, toluoyl or naphthoyl; substituted aroyl; phenyl(C_1-C_6)alkanoyl selected from the group consisting of phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutanoyl, phenylpentanoyl, phenylhexanoyl; naphthyl(C_1-C_6) alkenoyl selected from the group consisting of naphthylacetyl, naphthylpropenoyl and

naphthylbutanoyl; phenyl (C_3-C_6) alkenoyl selected from the group consisting of phenylpropenoyl, phenylbutenoyl, phenylmethacryloyl, phenylpentanoyl and phenylhexenoyl; naphthyl (C_3-C_6) alkenoyl selected from the group consisting of naphthylpropenoyl and naphthylbutenoyl; phenyl (C_1-C_6) alkoxycarbonyl; fluorenyl (C_1-C_6) alkoxycarbonyl; aryloxycarbonyl selected from the group consisting of phenoxycarbonyl and naphthyloxycarbonyl; aryloxy(lower)alkanoyl selected from the group consisting of phenoxyacetyl and phenoxypropionyl; arylcarbamoyl; arylthiocarbamoyl; arylglyoxyloyl selected from the group consisting of phenylglyoxyloyl and naphthylglyoxyloyl; or arylsulfonyl selected from the group consisting of phenylsulfonyl and p-tolylsulfonyl.

Claim 27. (New) The method of Claim 24, wherein said heterocyclicaliphatic acyl is heterocyclic(lower)alkanoyl selected from the group consisting of heterocyclicacetyl, heterocyclicpropanoyl, heterocyclicbutenoyl, heterocyclicpentanoyl and heterocyclichexanoyl; heterocyclic(lower)alkenoyl selected from the group consisting of heterocyclicpropanoyl, heterocyclicbutenoyl, heterocyclicpentenoyl and heterocyclichexenoyl or heterocyclicglyoxyloyl.

Claim 28. (New) The method of Claim 24, wherein said substituted aroyl is substituted by at least one substituent which is heterocyclic substituted by alkoxyaryl, heterocyclic substituted by lower alkoxy(lower)alkoxyaryl, heterocyclic substituted by lower alkoxy(higher)alkoxyaryl, heterocyclic substituted by cyclo(lower)alkyloxyaryl, heterocyclic substituted by heterocyclicaryl, heterocyclic substituted by cyclo(lower)alkylcyclo(lower)alkyl , heterocyclic substituted by aryl substituted by lower alkoxy(lower)alkoxyaryl , heterocyclic substituted by aryl having a cyclo(lower)alkylheterocyclic group.

Claim 29. (New) The method of Claim 24, wherein R_1 is benzoyl substituted by pentyloxyphenylisoxazolyl, benzoyl substituted by pentyloxyphenylimidazolthiadiazolyl, benzoyl substituted by methoxyhexyloxyphenylthiadiazolyl, benzoyl substituted by methoxyoctyloxyphenylthiadiazolyl, benzoyl substituted by methoxyheptyloxyphenylthiadiazolyl, benzoyl substituted by cyclohexyloxyphenylimidazothiadiazolyl, benzoyl substituted by dimethylmorpholinophenylimidazothiadiazolyl, benzoyl substituted by methoxyheptyloxyphenylpiperazinyl, benzoyl substituted by methoxyoctyloxyphenylpiperazinyl, benzoyl substituted by cyclohexylcyclohexylpiperazinyl, benzoyl substituted by methoxyethoxyphenylphenylthiadiazolyl, benzoyl substituted by methoxybutoxyphenylphenylthiadiazolyl, benzoyl substituted by ethoxypropoxyphenylphenylthiadiazolyl, benzoyl substituted by cyclohexylpiperazinylphenylimidazothiadiazolyl or benzoyl substituted bycyclohexylpiperazinylphenylimidazothiadiazolyl.

Claim 30. (New) A pharmaceutical composition for the prophylactic and/or therapeutic treatment of an infectious disease caused by *Aspergillus fumigatus*, which comprises:

an effective amount of the lipopeptide compound [I] in Claim 1 in combination with Amphotericin B, Itraconazole, Nikkomycin X or Flucytosine and optionally pharmaceutically acceptable carriers or excipients.